December 22, 2017
Fresenius expects meaningful positive effects from US tax reform
Fresenius expects meaningful positive effects from the tax reform legislation signed into law in the United States today. The new law goes into effect on January 1, 2018.
The new legislation triggers the revaluation of deferred tax liabilities. This results in a one-time book gain of approximately EUR 90 million, to be reflected in Fresenius’ 2017 Group net income1. Thereof, approximately EUR 30 million are attributable to Fresenius Kabi and approximately EUR 60 million2 to Fresenius Medical Care.
Fresenius will report FY17 results and provide FY18 guidance including details on recurring tax effects resulting from the US tax reform on February 27, 2018.
1 Net income attributable to shareholders of Fresenius SE & Co. KGaA
2 Based on Fresenius’ 31% shareholding in Fresenius Medical Care AG & Co. KGaA
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.